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Abstract
The structure activity relationships and molecular modeling of the uracil nucleotide-activated
P2Y6 receptor have been studied. A series of UDP analogues bearing substitutions of the ribose
moiety, the uracil ring, and the diphosphate group was synthesized and assayed for activity at the
human P2Y6 receptor. The uracil ring was modified at the 4-position, with the synthesis of 4-
substituted-thiouridine-5′-diphosphate analogues, as well as at positions 3 and 5. The effect of
modifications at the level of the phosphate chain was studied by preparing a cyclic 3′,5′-
diphosphate analogue, a 3′-diphosphate analogue and several dinucleotide diphosphates. 5-Iodo-
UDP 32 (EC50 0.15 μM) was equipotent to UDP, while substitutions of the 2′-hydroxyl (amino,
azido) greatly reduce potency. 2- and 4-Thio analogues, 20 and 21, respectively, were also
relatively potent in comparison to UDP. However, most other modifications greatly reduced
potency. Molecular modeling indicates that the β-phosphate of 5′-UDP and analogs is essential
for the establishment of electrostatic interactions with two of the three conserved cationic residues
of the receptor. Among 4-thioether derivatives, a 4-ethylthio analogue 23 displayed an EC50 of
0.28 μM, indicative of favorable interactions predicted for a small 4-alkylthio moiety with the
aromatic ring of Y33 in TM1. The activity of analogue 19 in which the ribose was substituted with
a 2-oxabicyclohexane ring in a rigid (S) conformation (P= 126°, 1′-exo) was consistent with
molecular modeling. These results provide a better understanding of molecular recognition at the
P2Y6 receptor and will be helpful in designing selective and potent P2Y6 receptor ligands
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Introduction
P2 nucleotide receptors consist of two families: G protein-coupled receptors designated
P2Y, which include 8 subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-P2Y14), and ligand-gated
cation channels designated P2X, which include 7 subtypes (P2X1-P2X7). All of these
subtypes have been cloned and functionally characterized.1-10 The family of P2Y receptors
can be further divided in two different subgroups based on overall sequence similarity,
coupling to specific G proteins, and second messenger responses. The P2Y1-like subgroup
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) is Gq-coupled and stimulates phospholipase C (PLC),
and the P2Y12-like subgroup (P2Y12, P2Y13, P2Y14) is Gi coupled and inhibits adenylyl
cyclase (AC).11 The distribution of P2Y receptors is broad, and certain of these are of
therapeutic interest including antithrombotic therapy, modulation of the immune system and
cardiovascular system, inflammation, pain, diabetes, and treatment of cystic fibrosis and
other pulmonary diseases.12-15 Whereas P2X receptors tend to be activated principally by
adenine nucleotides, P2Y receptors are activated by adenine and/or uracil nucleotides. The
P2Y2 receptor is activated by both uridine 5′-triphosphate (UTP) and adenosine 5′-
triphosphate (ATP), the P2Y4 receptor by UTP, the P2Y14 by UDP-glucose, and the P2Y6
receptor by uridine 5′-diphosphate (UDP 1, Chart 1).16
The P2Y6 receptor is distributed in various tissues including lung, heart, thymus, aorta,
bone, spleen, digestive tract, placenta and brain. This receptor has been implicated in
protection against apoptosis induced by TNFα,17 enhancement of osteoclast survival
through NF-κB activation,18 regulation of electrolyte transport in the airways,19 and
production of pro-inflammatory cytokines and chemokines,20,21 and growth and contraction
of vascular muscles.22
The SAR (structure activity relationship)of nucleotides in activating the human P2Y6
receptor has been probed (Chart 1). 5-Br-UDP 2, UDP-β-S 3 and the dinucleotide
triphosphate INS48823 (P1-((2-benzyl-1,3-dioxolo-4-yl)uridine 5′) P3-(uridine 5′)
triphosphate) 4 are potent and/or stable agonists of the P2Y6 receptor.5,18,19,22 We have
reported that the South (S) conformation of the ribose moiety is preferred for ligand
recognition by the P2Y6 receptor.23,35 The conformationally-constrained (N)-methanocarba
(mc) derivative 5 was inactive, and the (S)-methanocarba derivative 6 was moderately
potent in activating the P2Y6 receptor. Replacement of the uracil moiety with other
nucleobases 7–10 greatly reduced the potency at the human P2Y6 receptor.24 In order to
investigate more extensively the SAR at the P2Y6 receptor, we synthesized a series of UDP
analogues, where modifications at the level of uracil moiety, ribose ring and/or phosphate
chain have been introduced. Molecular modeling was carried out to predict sites of
interaction of the ligands with the P2Y6 receptor and to provide hypotheses for the design of
additional analogues.
To facilitate the comparison among receptors, throughout this paper we use the GPCR
residue indexing system, as explained in detail elsewhere.11
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Analogues of UDP 1 with modifications in the ribose ring, uracil moiety, and phosphate
chain, as well as dinucleotides (Table 1), were synthesized. The ribose ring was modified by
removal of the hydroxyl group at the 3′ position 13, replacement of the hydroxyl at the 2′
position with various functional groups, 15-18, and with the substitution of a 2-
oxabicyclohexane ring (2-OBH) in place of the ribose ring,25 which fixed the sugar moiety
in a rigid (S) conformation, 19. The uracil ring was modified at the 2 and 4 positions, with
the synthesis of 2-thiouridine diphosphate 20 and 4-substituted-thiouridine diphosphates
analogues 22-30, and at the 3 and 5 positions with 31 and 32 respectively. Finally, the
synthesis of 2′-deoxy-2′-aminouridine 3′-diphosphate 17, the cyclic 3′,5′-diphosphate 33
and the dinucleotides 34-37 as byproducts has allowed us to study modifications at the level
of the phosphate chain. All the nucleotide analogues were prepared in their ammonium or
triethyl ammonium salt form according to the methods shown in Schemes 1-5 and tested in
functional assays of the P2Y6 receptor (Table 1). The nucleotide analogues were
characterized using nuclear magnetic resonance (NMR, 1H, 13C, 31P and COSY), and high-
resolution mass spectrometry.
The nucleotide diphosphates were obtained following two different methods of
phosphorylation. The one-pot method using a sequential reaction with phosphorous
oxychloride and phosphoric acid tributylammonium salt26 provided the 5′-diphosphate
analogues 13, 15, 16, 18-20 in moderate yields (Schemes 1, 2). The phosphorylation of the
2′-amino-2′-deoxyuridine 40 using the one-pot method provided the 3′-diphosphate
derivative 17. The 1H NMR of compound 17 shows peaks at 5.01 ppm (H-3′) and 3.89 ppm
(H-5′), when the chemical shifts of 5′-diphosphate uridine analogues are usually at
4.65-4.35 ppm (H-3′) and 4.40-4.15 ppm (H-5′). These results combined with 31P NMR
and HRMS indicate that for 17 the diphosphate group is in 3′ position. The synthesis of 2′-
deoxy-2′-aminouridine-5′-diphosphate 16 was accomplished after the acetylation of the
amino group in 40 with a trifluoroacetyl group to obtain 41. Phosphorylation of the 2′-
trifluoroacetylamino derivative 41 followed by an in situ deprotection of the 2′-amine
provided the 5′-diphosphate analogue 16. Compound 16 was also obtained by reduction of
the 2′-deoxy-2′-azidouridine-5′-diphosphate 15 with H2 and Pd/C. The NMR spectrum for
16 shows peaks at 4.61 ppm (H-3′) and 4.24, 4.16 ppm (H-5′) in accordance with others 5′-
diphosphates derivatives. The preparation of compounds 28, 30 and 32 was accomplished by
another method, i.e. activation of the 5′-monophosphate by reaction with 1,1′-
carbonyldiimidazole followed by the addition of phosphoric acid tributylammonium salt23 to
provide the corresponding diphosphate (Schemes 4, 5).
The synthesis of various 4-substituted-thiouridine nucleosides and nucleotides from uridine
was described previously,27-29 and various methods of S-alkylation were applied to a purine
nucleoside, 2-thioadenosine.26,30 By adapting these alkylation procedures, we have
developed a more direct synthesis of 4-substituted-thiouridine nucleotides starting with the
commercially available 4-thiouridine 5′-diphosphate (4-thio-UDP) 21 that allowed us to
obtain the final compounds in only two steps (Scheme 3).
The treatment of 4-thio-UDP with 0.25 M NaOH in methanol for 2 h at room temperature
gave the corresponding sodium thiolate salt, which appeared as a yellow solid after the
solvent was lyophilized. The nucleotide diphosphate sodium salt was selectively S-alkylated
by reacting with an excess of the corresponding alkyl halide at room temperature and using
dimethylformamide as solvent. Compounds 22-27, and 29 were obtained following this
procedure. Because of stability problems the ester derivatives 45 and 46 were directly
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subjected to hydrolysis without purification by treatment with 0.25 M NaOH at room
temperature to afford the corresponding acid derivatives 26 and 29, respectively.
Nucleoside 5′-diphosphates are generally less stable than the corresponding
monophosphates. For this reason, for alkyl halides in which heating is necessary for the
alkylation reaction, the starting material was the commercially available 4-thiouridine 5′-
monophosphate (4-thio-UMP) 47 (Scheme 4). After the formation of the sodium thiolate salt
of the 4-thio-UMP, the thio group of the uracil moiety was alkylated following the same
procedure as in Scheme 3. The alkylthio monophosphates obtained were converted to the
corresponding diphosphates through a phosphoryl imidazolide intermediate, which reacted
with phosphoric acid tributylammonium salt.23 Compounds 28 and 30 were obtained
following this procedure. The ester derivatives 48 and 49, because of stability problems,
were directly subjected to next reaction without purification.
The nucleotides were selectively S-alkylated using the procedures described above. The 13C
NMR spectrum of the amide derivative 27 shows the peak corresponding to the methylene
of the acetamide at 33.0 ppm, typical of a carbon-sulfur bond.
Pharmacological Activity
Activation of PLC by the nucleotide derivatives was studied in 1321N1 astrocytoma cells
stably expressing the human P2Y6 receptor.16,31 Removal of the 2′- or 3′-hydroxyl group of
UDP led to a >100-fold decrease in potency in 12 and 13, respectively Substitution of the
2′-hydroxyl group of UDP with an azido or amino groups in 15, and 16, respectively,
greatly reduced potency. The P2Y6 receptor is highly selective for 5′-diphosphate
derivatives. Thus, uridine 5′-monophosphate 11, 2′-deoxyuridine 3′,5′-bisphosphate 1432
and a uridine 3′-diphosphate derivative 17 were inactive as either agonists or antagonists.
Rigid ring systems also were used to determine the preferred ribose conformation at the
P2Y6 binding site. As previously reported, a strong preference for the (S) conformation was
indicated (cf. 6 vs. 5). Another rigid ring system (2-OBH) in 19 was tolerated at the P2Y6
binding site.
Among uracil modified compounds, 2-thio-UDP 20 and 4-thio-UDP 21 were prepared and
tested in order to probe the effect of the electronegativity as well as the size of the exocyclic
atoms at positions 2 and 4. Both derivatives were five-fold less potent than the parent
compound UDP. Among uncharged alkylated derivatives of 21, the highest potency was
observed with the S-ethyl analogue 23, which was 20-fold less potent than UDP. In the
series of carboxyalkylthio ethers, the highest potency was observed with the S-
carboxyethylthio analogue 28. Substitution at the 3-position in 31 markedly decreased
potency, while halogenation of the 5-position in the iodo analogue 32 resulted in a molecule
that was equal in potency to UDP. By analogy, a 5-bromo analogue was previously reported
to be roughly equipotent to UDP.16
The cyclic 3′,5′-diphosphate 33, which can be considered a closely related cyclized
analogue of bisphosphate 14, was inactive at the P2Y6 receptor. The dinucleotide 34 was
moderately potent at the P2Y6 receptor. 4-Thioether modification at both nucleobases in 35
and 36 reduced potency. A 4-O or 4-S was required for P2Y6 receptor activation, since the
corresponding NH analogue 37 was inactive.
Within a series of uracil dinucleotide 5′,5′-polyphosphates, the triphosphates were the most
potent and selective at the human P2Y6 receptor. However, dinucleotide 5′,5′-diphosphates
also showed selectivity for the P2Y6 receptor.33,34 Therefore, several dinucleotide
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diphosphates 34–37, including 4-alkylthio analogues, were compared in this study. Only the
simple Up2U 34 displayed substantial μmolar potency at the P2Y6 receptor.
Molecular Modeling
Docking studies of selected compounds were conducted at the model of the membrane-
embedded human P2Y6 receptor.35 The binding mode of each studied compound was
obtained by subjecting the complex to two distinct conformational searches, performed
sequentially. These searches were intended to exhaustively explore the possible docking
poses of the ligand by means of rotations and translations of the small molecule within the
binding pocket. Simultaneously, the conformation of the residues lining the pocket was
rearranged to minimize the energy of interaction with the ligand.
A schematic representation of the entire structure of the P2Y6 receptor complexed with 32 is
given in Figure 1a, while Figure 1b shows the details of the receptor-ligand interactions. In
analogy with our previous P2Y6-UDP complex,35 the diphosphate moiety of 32 is
coordinated by three cationic residues from transmembrane domain (TM) 3, TM6, and TM7,
namely 3.29, 6.55, and 7.39. The O at position 2 and the NH at position 3 of the uracil ring
are H-bonded with S291(7.43) and Y33(1.33), respectively. Consistently with the
equipotency of 32 and UDP, the 5-iodo group does not show any sort of steric or electronic
incompatibility with the features of the P2Y6 binding pocket. Figure 1c shows compound 6
docked into the putative binding pocket of the P2Y6 receptor model. The locked puckering
of the pseudoribose ensures that the phosphate and the nucleobase moiety of 6 maintain the
optimal geometry for the interaction with the P2Y6 binding pocket. The donation of an H-
bond from the NH at position 3 of the uracil ring to Y33(1.39), even though not essential for
the recognition of the nucleotides, apparently contributes to enhanced potency at the P2Y6
receptor. Compound 31, which is incapable of donating an H-bond to Y33(1.39) due to the
methyl substituent at the N3 position (Figure 1d), exhibited a 250-fold lower potency than
UDP. A decreased partial negative atomic charge on the N3 might contribute to the
decreased potency of 4-thio-UDP (21), as a consequence of a weaker H-bond donation to
Y33(1.39). Moreover, all the 4-thio substituted compounds, which are incapable of donating
an H-bond to Y33(1.39), exhibited lower potency than the parent compound 4-thio-UDP
(21). Among these molecules, 4-ethylthio-UDP (23), 4-allylthio-UDP (24), and 4-
benzylthio-UDP (25) showed the highest potency. Molecular modeling results suggest that
the hydrophobic substituents at position 4 of the uracil ring establish favorable interactions
with the aromatic ring of Y33(1.39) and with an hydrophobic pocket located between TM1
and TM2 (Figure 1e). The substitution at the 4-position with carboxyalkylthioethers (26, 28,
29) is also well tolerated by the receptor. These target structures were designed on the basis
of molecular modeling results to engage an electrostatic interaction with K204(7.36) (Figure
1f).
Discussion
As a result of mutagenesis and molecular modeling studies, we proposed that nucleotides
bind to the P2Y receptor with the sugar moiety accommodated between TM3 and TM7, the
base pointing toward TM1 and TM2, and the polyphosphate moiety pointing in the direction
of TM6 (Figure 1a).11,35,36 According to this model, the electrostatic interaction of the
phosphate moiety with three cationic residues from TM3, TM6, and TM7 (3.29, 6.55, and
7.39) is fundamental for the recognition of nucleotides. Our current modeling data (Figure 1)
suggest that the β-phosphate of UDP and related analogs is fundamental for the
establishment of electrostatic interactions with two of the three cationic residues, namely
K259(6.55) and R287(7.39). Not surprisingly, compounds 11, 14, 17, and 33, which lack a
β-phosphate linked through the 5′-position of ribose, were inactive at the P2Y6 receptor.
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The puckering of the ribose ring, described by the phase angle of pseudorotation (P, Figure
2), is of fundamental importance for the biological activity of nucleosides and nucleotides.
We recently discovered that the (S) conformation of the ribose moiety is preferred for ligand
recognition by the P2Y6 receptor.35 Our molecular modeling studies suggested that a pure
(S) conformation (P= 180°, 2′-endo, 3′-exo) would confer to the phosphate and nucleobase
moieties of UDP the most favorable orientation for establishment of interactions with the
residues from TM1, TM3, TM6, and TM7. Compound 6, which is locked in the (S)
conformation (P= -162°, 3′-exo) by a (S)-methanocarba (mc) ring, proved to be about 10
times more potent than 12. Conversely, 5, locked in the (N) conformation by a (N)-
methanocarba ring, was found completely inactive. Compound 19, which is locked in a (S)
conformation (P= 126°, 1′-exo) by a 2-OBH ring system, but is further away from pure (S)
than 6, maintained agonist activity at the P2Y6 receptor but was less potent than the
corresponding flexible analogues. The proposed conformation of 19 was calculated using
quenched molecular dynamics and energy minimization. The cyclopropane ring, fused
between C3′ and C4′, forces the C1′ into the exo conformation in order for the six-
membered ring to adopt a pseudoboat conformation.
Table 2 shows the relative EC50 values with respect to the native ligands at three P2Y
receptors for the same changes in the base or nucleotide, applied to the 5′-diphosphate
derivative (P2Y6 receptor) and to the 5′-triphosphate derivative (P2Y2 and P2Y4 receptors).
In most cases, there is a parallel reduction of potency at P2Y2 and P2Y4 receptors. However,
there tended to be a greater loss of potency at the P2Y6 receptor, for example for 2′-ribose
modifications. The removal of the 2′- or 3′-hydroxyl group was more poorly tolerated at the
P2Y6 receptor than at the two other subtypes. The reduction of potency of the 2′-
deoxyarabino-2′-fluoro analogue 18 was particularly pronounced at the P2Y6 receptor. The
low potency of the 2′-amino analogue 16 is in sharp contrast with the high potency of the
corresponding triphosphate at the P2Y2 receptor.37 The 2- and 4-thio modifications tended
to preserve potency at all subtypes, but most effectively at the P2Y2 and P2Y4 receptors.
Strikingly, the 5-iodo modification preserves potency most effectively at the P2Y6 receptor,
and 5-halo substitution of the uracil ring may therefore be a basis for achieving selectivity at
this subtype.
Conclusions
The P2Y receptor family is unusual in comparison to other pharmacologically-defined
clusters of GPCR sequences in that they respond to varied and diverse nucleotide ligands.
Within the same phylogenetic cluster are receptors for other anionic ligands:
lysophosphatidylserine (GPR34), succinic acid (GPR91), and α-keto-glutarate (GPR80).1,11
The challenge for the medicinal chemist is to understand the structural basis for the P2Y
ligand selectivities and to use that information to design much needed pharmacological
probes to act as selective agonists and antagonists. We have recently focused on the
influence of the ribose conformation on subtype selectivity. In this study of SAR at the
human P2Y6 receptor following diverse structural changes of UDP, we have identified
various modifications that deselect for this receptor subtype in relation to other uracil
nucleotide-responsive receptors and several modifications (i.e. 5-iodo and the (S)-mc ring)
that provide P2Y6 selectivity. Combinations of these various modifications should achieve
higher potency and selectivity, and in conjunction with molecular modeling and receptor
docking studies should lead to high affinity agonists that are highly selective for the P2Y6
receptor.
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2′-Deoxyuridine-5′-diphosphate (12) was purchased from Jena Bioscience USA (San
Diego, CA). 3′-Deoxyuridine-5′-triphosphate was purchased from TriLink BioTechnologies
(San Diego, CA). 3′-Deoxyuridine (38) was purchased from T.R.C., Inc. (North York,
Ontario, Canada). 2′-Azido-2′-deoxyuridine (39), and 2′-amino-2′-deoxyuridine (40) were
purchased from CMS Chemicals Ltd. (Oxfordshire, UK). 2′-Arafluoro-2′-deoxyuridine
(42b) was purchased from R.I. Chemical, Inc. (Orange, CA). 2-Thiouridine (43) was
purchased from Berry & Associates, Inc (Dexter, MI). Compounds 21, 47, 53 and reagents
and solvents were purchased from Sigma-Aldrich (St. Louis, MO). Compounds 5, 6, 14, 31
were synthesized in our laboratory as described,23,32,35,37. Compounds 34, 37 and 44 were
synthesized as reported.25,38,39
1H NMR spectra were obtained with a Varian Gemini 300 spectrometer using D2O as a
solvent. The chemical shifts are expressed as relative ppm from HOD (4.78 ppm). 13C NMR
spectra were recorded at room temperature by use of Varian XL 300 spectrometer (75
MHz); methanol-d4 was used as an external standard. 31P NMR spectra were recorded at
room temperature by use of Varian XL 300 spectrometer (121.42 MHz); orthophosphoric
acid (85%) was used as an external standard. The complete assignment of the signals was
performed by COSY experiments obtained with a Varian XL 300 spectrometer.
Purity of compounds was checked using a Hewlett–Packard 1100 HPLC equipped with a
Luna 5 μ RP-C18(2) analytical column (250 X 4.6 mm; Phenomenex, Torrance, CA).
System A: linear gradient solvent system: 5 mM TBAP (tetrabutylammonium
dihydrogenphosphate)-CH3CN from 80:20 to 40:60 in 20 min, then isocratic for 2 min; the
flow rate was 1 mL/min. System B: linear gradient solvent system: 10 mM TEAA
(triethylammonium acetate)-CH3CN from 100:0 to 85:15 in 20 min, then isocratic for 2 min;
the flow rate was 1 mL/min. System C: linear gradient solvent system: 10 mM TEAA-
CH3CN from 90:10 to 60:40 in 20 min, then isocratic for 2 min; the flow rate was 1 mL/
min. Purity of compounds 13, 15-17, 20, 25, 29, 32, 50 and 51 in system B or C was
checked using a Zorbax Eclipse 5 μm XDB-C18 analytical column (250 X 4.6 mm; Agilent
Technologies Inc, Palo Alto, CA). Peaks were detected by UV absorption with a diode array
detector. All derivatives tested for biological activity showed >98% purity in the HPLC
systems.
High-resolution mass measurements were performed on Micromass/Waters LCT Premier
Electrospray Time of Flight (TOF) mass spectometer coupled with a Waters HPLC system.
Purification of the nucleotide analogues for biological testing was carried out on
(diethylamino)ethyl (DEAE)-A25 Sephadex columns as described below. Compounds 13,
15-17 were additionally purified by HPLC using system D (10 mM TEAA-CH3CN from
100:0 to 90:10 in 30 min, then isocratic for 2 min; the flow rate was 2 mL/min) with a Luna
5 μ RP-C18(2) semipreparative column (250 X 10.0 mm; Phenomenex, Torrance, CA).
General Procedure for the Preparation of Nucleoside 5′-Diphosphates
Procedure A. A solution of the corresponding nucleoside (0.04-0.19 mmol) and Proton
Sponge (1.5 equiv) in trimethyl phosphate (2 mL) was stirred for 10 min at 0 °C. Then
phosphorous oxychloride (2 equiv) was added dropwise, and the reaction mixture was
stirred for 2 hours at 0 °C. A mixture of tributylamine (9 equiv) and a solution 0.35 M of
bis(tributylammonium) salt of phosphoric acid in DMF (6 equiv) was added at once. This
salt was prepared by mixing tributylamine (0.16 mL, 0.66 mmol) and phosphoric acid (34
mg, 0.35 mmol) in DMF (1 mL). After 6 min 0.2 M triethylammonium bicarbonate solution
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(3 mL) was added, and the clear solution was stirred at room temperature for 45 min. The
latter was lyophilized overnight. The residue was purified by ion-exchange column
chromatography using a Sephadex-DEAE A-25 resin with a linear gradient (0.01-0.5 M) of
0.5 M ammonium bicarbonate as the mobile phase. The corresponding nucleoside
diphosphates were collected, frozen and lyophilized as the ammonium salts.
(2R,3R,5S)-1-(5-(Diphosphoryloxymethyl)-3-hydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,
3H)-dione, Triethylammonium salt (13)
Procedure A Compound 13 (2 mg, 7%) was obtained as a white solid from 38 (10 mg, 0.04
mmol). 1H NMR (D2O) δ 8.04 (d, J=8.1 Hz, 1H), 5.94 (d, J=8.1 Hz, 1H), 5.85 (d, J=1.5 Hz,
1H), 4.68 (m, 1H), 4.55 (m, 1H), 4.35 (m, 1H), 4.14 (m, 1H), 2.25 (m, 1H), 2.10 (m,
1H); 31P NMR (D2O) δ -10.33 (d, J=20.8 Hz), -10.79 (d, J=19.6 Hz); HRMS m/z found
386.9995 (M – H+)-. C9H13N2O11P2 requires 386.9995; HPLC (System A) 13.7 min (98%),
(System B) 6.7 min (98%).
(2R,3R,4S,5R)-1-(3-Azido-5-(diphosphoryloxymethyl)-4-hydroxytetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione, Triethylammonium salt (15)
Procedure A Compound 15 (12 mg, 35%) was obtained as a white solid from 39 (32 mg,
0.12 mmol). 1H NMR (D2O) δ 7.99 (d, J=8.1 Hz, 1H), 6.04 (d, J=5.1 Hz, 1H), 5.99 (d, J=8.1
Hz, 1H), 4.63 (m, 1H), 4.40 (m, 1H), 4.29 (m, 1H), 4.25 (m, 2H); 31P NMR (D2O) δ -9.63,
-10.81; HRMS m/z found 427.9993 (M – H+)-. C9H12N5O11P2 requires 428.0009; HPLC
(System A) 13.9 min (99%), (System B) 9.8 min (99%).
(2R,3R,4S,5R)-N-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide (41)
To a solution of 40 (20 mg, 0.08 mmol) in DMF (1 mL) was added DIEA (0.04 mL, 0.25
mmol) and ethyltrifluoroacetate (0.03 mL, 0.25 mmol). The reaction mixture was stirred at
room temperature for 16 h. The solvent was removed in vacuo, and the residue was purified
by preparative thin layer chromatography (CH2Cl2-MeOH, 85:15) to afford 41 (24 mg,
86%) as a white solid. 1H NMR (CD3OD) δ 8.01 (d, J=8.1 Hz, 1H), 6.13 (d, J=7.8 Hz, 1H),
5.73 (d, J=8.1 Hz, 1H), 4.60 (m, 1H), 4.31 (m, 1H), 4.01 (m, 1H), 3.77 (m, 2H); HRMS m/z
found 338.0587 (M – H+)-. C11H11N3O6F3 requires 338.0600.
(2R,3R,4S,5R)-1-(3-Amino-5-(diphosphoryloxymethyl)-4-hydroxytetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione (16)
Procedure A Compound 16 in the triethylammonium salt (7 mg, 17%) was obtained as a
white solid from 41 (20 mg, 0.06 mmol). Alternatively, compound 16 (0.6 mg, 75%) was
obtained by treatment of a solution of the triethylammonium salt of compound 15 (1.5 mg,
0.002 mmol) in MeOH (1 mL) with 10% Pd/C (0.5 mg) and H2 at atmospheric pressure for
1 h at room temperature. 1H NMR (D2O) δ 7.99 (d, J=7.5 Hz, 1H, H-6 pyrimidine), 6.12 (d,
J=7.2 Hz, 1H, H-2), 6.00 (d, J=7.5 Hz, 1H, H-5 pyrimidine), 4.61 (m, 1H, H-4), 4.36 (m,
1H, H-5), 4.24 (m, 1H, HCHO), 4.16 (m, 1H, HCHO), 3.88 (m, 1H, H-3); 31P NMR (D2O)
δ -6.77, -10.57; HRMS m/z found 402.0126 (M – H+)-. C9H14N3O11P2 requires 402.0104;
HPLC (System A) 6.0 min (99%), (System B) 7.1 min (99%).
(2R,3R,4S,5R)-1-(3-Amino-4-(diphosphoryloxy)-5-(hydroxymethyl)-tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione, Triethylammonium salt (17)
Procedure A Compound 17 (6 mg, 8%) was obtained as a white solid from 40 (25 mg, 0.10
mmol). 1H NMR (D2O) δ 7.88 (d, J=8.1 Hz, 1H, H-6 pyrimidine), 6.29 (d, J=6.9 Hz, 1H,
H-2), 5.91 (d, J=8.1 Hz, 1H, H-5 pyrimidine), 5.01 (m, 1H, H-4), 4.46 (m, 1H, H-5), 4.14
(m, 1H, H-3), 3.89 (m, 2H, CH2O); 13C NMR (D2O) δ 167.3, 152.9, 142.4, 103.9, 87.9,
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87.5, 74.7, 62.0, 56.3; 31P NMR (D2O) δ -7.73 (d, J=22.0 Hz), -11.16 (d, J=22.0 Hz);
HRMS m/z found 402.0094 (M – H+)-. C9H14N3O11P2 requires 402.0104; HPLC (System
A) 10.6 min (98%), (System B) 6.7 min (98%).
(2R,3S,4R,5R)-1-(5-(Diphosphoryloxymethyl)-3-fluoro-4-hydroxytetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione, Ammonium salt (18)
Procedure A Compound 18 (2.1 mg, 32%) was obtained as a white solid from 42b (9 mg,
0.04 mmol). 1H NMR (D2O) δ 7.79 (d, J=7.9 Hz, 1H), 6.36 (m, 1H), 5.93 (d, J=7.9 Hz, 1H),
5.53 (apparent dt, JH-F=69.0 Hz, 1H), 4.42 (m, 1H), 4.19 (m, 3H); 31P NMR (D2O) δ -8.89,
-10.81; HRMS m/z found 404.9892 (M – H+)-. C9H12N2O11P2F requires 404.9900; HPLC
(System A) 15.1 min (99%), (System B) 10.9 min (99%).
(1S,3R,4R,5S)-1-(4-Hydroxy-1-(diphosphoryloxymethyl)-2-oxabicyclo[3.1.0]hexan-3-
yl)pyrimidine-2,4(1H,3H)-dione, Ammonium salt (19)
Procedure A Compound 19 (4 mg, 31%) was obtained as a white solid from 44 (10 mg,
0.04 mmol). 1H NMR (D2O) δ 7.80 (d, J=8.1 Hz, 1H), 5.79 (d, J=8.1 Hz, 1H), 5.60 (d, J=8.1
Hz, 1H), 4.65 (m, 1H), 4.07(m, 1H), 3.67(m, 1H), 1.81 (m, 1H), 1.37 (m, 1H), 0.84 (m,
1H); 31P NMR (D2O) δ -7.08, -10.55; HRMS m/z found 398.9985 (M – H+)-.
C10H13N2O11P2 requires 398.9995; HPLC (System A) 14.5 min (99%), (System B) 10.2
min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-2-
thioxo-2,3-dihydropyrimidin-4(1H)-one, Ammonium salt (20)
Procedure A Compound 20 (21 mg, 23%) was obtained as a white solid from 38 (50 mg,
0.19 mmol). 1H NMR (D2O) δ 8.19 (d, J=8.1 Hz, 1H), 6.65 (d, J=2.7 Hz, 1H), 6.27 (d, J=8.1
Hz, 1H), 4.45 (m, 1H), 4.32 (m, 4H); 31P NMR (D2O) δ -9.35 (d, J=20.8 Hz), -10.84 (d,
J=20.8 Hz); HRMS m/z found 418.9712 (M – H+)-. C9H13N2O11P2S requires 418.9715;
HPLC (System A) 15.0 min (98%), (System B) 8.4 min (98%).
General Procedure for the Preparation of 4-Substituted-Thio-UDP Analogues
Procedure B. To a suspension of 4-thiouridine 5′-diphosphate (5 mg, 0.01 mmol) in MeOH
(1 mL) was added 0.25 M NaOH (0.14 mL). The reaction mixture was stirred at room
temperature for 2 h and then the solvent was eliminated under high vacuum. The 4-thio-
UDP sodium salt obtained was suspended in dry DMF (1.5 mL) and an excess of the
corresponding alkyl halide (50 equiv) was added. The reaction mixture was stirred at room
temperature for 24 h, the progress of the reaction was monitored by analytical HPLC
(System A). After removal of the solvent, the residue was purified using the same method
than in procedure A, and the corresponding nucleotide diphosphates were obtained as the
ammonium salts.
Procedure C. To a solution of 4-thiouridine 5′-monosphate (10 mg, 0.03 mmol) in MeOH
(1 mL) was added 0.25 M NaOH (0.13 mL). The reaction mixture was stirred at room
temperature for 2 h and then the solvent was eliminated under high vacuum. The 4-thio-
UMP sodium salt obtained was suspended in dry DMF (2 mL) and an excess of the
corresponding alkyl halide (50 equiv) was added. The reaction mixture was stirred at 90 °C
for 4-8 h, the progress of the reaction was monitored by analytical HPLC (System A). The
solvent was removed in vacuo to obtain the corresponding 4-substituted-thio-UMP as a
crude solid, which then was used directly in the next step without further purification. To a
solution of the crude solid containing 4-substituted-thio-UMP in DMF (1.5 mL) was added
1,1′-carbonyldiimidazole (26 mg, 0.16 mmol). The reaction mixture was stirred at room
temperature for 6 h. Then 5% triethylamine solution in 1/1 water/methanol (3 mL) was
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added and stirring was continued at room temperature for additional 2 h. After removal of
the solvent, the residue was dried in high vacuum and dissolved in DMF (1 mL). To this
solution was successively added tributylamine (0.11 mL, 0.46 mmol) and a solution 0.35 M
of bis(tributylammonium) salt of phosphoric acid in DMF (0.4 mL). The reaction mixture
was stirred at room temperature for 2 days and then 0.2 M triethylammonium bicarbonate
was added. After removal of the solvent, the residue was purified using the same method
than in procedure A, and the corresponding nucleotide diphosphates were obtained as the
ammonium salts.
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-4-
(methylthio)pyrimidin-2(1H)-one, Ammonium salt (22)
Procedure B Compound 22 (7 mg, 80%) was obtained as a white solid from 21 (10 mg,
0.02 mmol) and using iodomethane as alkylating agent. 1H NMR (D2O) δ 8.25 (d, J=7.1 Hz,
1H), 6.76 (d, J=7.1 Hz, 1H), 5.94 (d, J=2.4 Hz, 1H), 4.41 (m, 1H), 4.32 (m, 4H), 2.54 (s,
3H); 13C NMR (D2O) δ 182.4, 156.8, 142.0, 106.4, 91.9, 83.8, 76.0, 69.6, 65.0, 14.0; 31P
NMR (D2O) δ -7.15 (d, J=23.1 Hz), -10.67 (d, J=23.1 Hz); HRMS m/z found 432.9888 (M
– H+)-. C10H15N2O11P2S requires 432.9872; HPLC (System A) 14.9 min (99%), (System B)
11.1 min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-4-
(ethylthio)pyrimidin-2(1H)-one, Ammonium salt (23)
Procedure B Compound 23 (2 mg, 44%) was obtained as a white solid using iodoethane as
alkylating agent and stirring the reaction mixture at 70 °C for 4 h. 1H NMR (D2O) δ 8.24 (d,
J=7.4 Hz, 1H), 6.75 (d, J=7.4 Hz, 1H), 5.94 (d, J=2.4 Hz, 1H), 4.41 (m, 1H), 4.32 (m, 4H),
3.15 (q, J=7.5 Hz, 2H), 1.36 (t, J=7.5 Hz, 3H); 31P NMR (D2O) δ -7.49, -10.73; HRMS m/z
found 447.0032 (M – H+)-. C11H17N2O11P2S requires 447.0028; HPLC (System A) 14.7
min (99%), (System B) 14.5 min (99%).
(2R,3R,4S,5R)-4-(Allylthio)-1-(3,4-dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-
yl)pyrimidin-2(1H)-one, Ammonium salt (24)
Procedure B Compound 24 (3.4 mg, 73%) was obtained as a white solid using allyl
bromide as alkylating agent. 1H NMR (D2O) δ 8.26 (d, J=7.5 Hz, 1H), 6.76 (d, J=7.5 Hz,
1H), 5.99 (m, 1H), 5.93 (m, 1H), 5.40 (d, J=17.1 Hz, 2H), 5.23 (d, J=10.2 Hz, 2H), 4.43 (m,
1H), 4.32 (m, 4H), 3.84 (d, J=6.6 Hz, 2H); 31P NMR (D2O) δ -6.08 (d, J=21.9 Hz), -10.55
(d, J=21.9 Hz); HRMS m/z found 459.0039 (M – H+)-. C12H17N2O11P2S requires 459.0028;
HPLC (System A) 16.0 min (99%), (System B) 16.2 min (99%).
(2R,3R,4S,5R)-4-(Benzylthio)-1-(3,4-dihydroxy-5-
(diphosphoryloxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, Ammonium salt (25)
Procedure B Compound 25 (3.3 mg, 65%) was obtained as a white solid using benzyl
bromide as alkylating agent. 1H NMR (D2O) δ 8.21 (d, J=7.2 Hz, 1H), 7.52 (m, 2H), 7.39
(m, 3H), 6.73 (d, J=7.2 Hz, 1H), 5.95 (d, J=2.7 Hz, 1H), 4.46 (s, 2H), 4.34 (m, 4H), 4.23 (m,
1H); 31P NMR (D2O) δ -9.41, -10.93; HRMS m/z found 509.0171 (M – H+)-.
C16H19N2O11P2S requires 509.0185; HPLC (System A) 16.8 min (98%), (System C) 7.9
min (98%).
(2R,3R,4S,5R)-2-(1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-2-
oxo-1,2-dihydropyrimidin-4-ylthio)acetic acid, Ammonium salt (26)
Procedure B Compound 45 (HPLC (System A) 15.6 min) was obtained as a crude solid
using methyl bromoacetate as alkylating agent. The residue that contained compound 45 was
dissolved in H2O (1 mL) and 0.25 M NaOH (0.5 mL) was added. The reaction mixture was
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stirred at room temperature for 2 h. After removal of the solvent, the residue was purified
following the general procedure to give compound 26 (2.4 mg, 49% from 21) as a white
solid. 1H NMR (D2O) δ 8.21 (d, J=7.1 Hz, 1H), 6.75 (d, J=7.1 Hz, 1H), 5.96 (d, J=2.4 Hz,
1H), 4.35 (m, 4H), 4.25 (m, 1H), 3.88 (s, 2H); 31P NMR (D2O) δ -10.37 (d, J=20.6 Hz),
-10.92 (d, J=20.6 Hz); HRMS m/z found 476.9773 (M – H+)-. C11H15N2O13P2S requires
476.9770; HPLC (System A) 18.3 min (99%), (System B) 9.0 min (99%)
(2R,3R,4S,5R)-2-(1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-2-
oxo-1,2-dihydropyrimidin-4-ylthio)acetamide, Ammonium salt (27)
Procedure B Compound 27 (3.8 mg, 79%) was obtained as a white solid using
iodoacetamide as alkylating agent. 1H NMR (D2O) δ 8.31 (d, J=7.4 Hz, 1H), 6.79 (d, J=7.4
Hz, 1H), 5.92 (d, J=1.5 Hz, 1H), 4.42 (m, 1H), 4.32 (m, 4H), 3.96 (s, 2H); 13C NMR (D2O)
δ 177.9, 173.9, 156.0, 141.9, 105.8, 91.2, 83.0, 75.1, 68.3, 63.8, 33.0; 31P NMR (D2O) δ
-7.63, -10.66 (d, J=21.9 Hz); HRMS m/z found 475.9935 (M – H+)-. C11H16N3O12P2S
requires 475.9930; HPLC (System A) 14.6 min (99%), (System B) 8.6 min (99%).
(2R,3R,4S,5R)-3-(1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-2-
oxo-1,2-dihydropyrimidin-4-ylthio)propanoic acid, Ammonium salt (28)
Procedure C Compound 49 (HPLC (System A) 16.0 min) was obtained as a crude solid
using methyl 3-bromopropionate and stirring at 90 °C for 8h in the alkylation reaction. The
residue that contained compound 49 was dissolved in H2O (1 mL) and 0.25 M NaOH (2
mL) was added. The reaction mixture was stirred at room temperature for 6 h. After removal
of the solvent, the residue was purified following the general procedure to give compound
28 (2.8 mg, 20% from 47) as a white solid. 1H NMR (D2O) δ 8.21 (d, J=7.2 Hz, 1H), 6.76
(d, J=7.2 Hz, 1H), 5.99 (d, J=2.7 Hz, 1H), 4.38 (m, 4H), 4.26 (m, 1H), 3.39 (t, J=6.9 Hz,
2H), 2.73 (t, J=6.9 Hz, 2H); 31P NMR (D2O) δ -10.39, -10.84; HRMS m/z found 490.9951
(M – H+)-. C12H17N2O13P2S requires 490.9927; HPLC (System A) 18.5 min (99%),
(System B) 9.6 min (99%).
(2R,3R,4S,5R)-4-(1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-2-
oxo-1,2-dihydropyrimidin-4-ylthio)butanoic acid, Ammonium salt (29)
Procedure B Compound 46 (HPLC (System A) 16.4 min) was obtained as a crude solid
using methyl 4-iodobutyrate as alkylating agent and stirring the reaction mixture at 50 °C for
20 h. The residue that contained compound 46 was dissolved in H2O (2 mL) and 0.25 M
NaOH (2 mL) was added. The reaction mixture was stirred at room temperature for 2 h.
After removal of the solvent, the residue was purified following the general procedure to
give compound 29 (2.0 mg, 16% from 21) as a white solid. 1H NMR (D2O) δ 8.19 (d, J=6.8
Hz, 1H), 6.75 (d, J=6.8 Hz, 1H), 5.96 (m, 1H), 4.35 (m, 4H), 4.24 (m, 1H), 3.19 (d, J=7.1
Hz, 1H), 2.40 (d, J=7.5 Hz, 1H), 1.99 (m, 2H); 31P NMR (D2O) δ -10.22, -10.98; HRMS m/
z found 505.0096 (M – H+)-. C13H19N2O13P2S requires 505.0083; HPLC (System A) 18.2
min (99%), (System B) 9.2 min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(monophosphoryloxymethyl)tetrahydrofuran-2-yl)-4-
(hexylthio)pyrimidin-2(1H)-one, Ammonium salt (50)
To a solution of 4-thiouridine 5′-monosphate (10 mg, 0.03 mmol) in MeOH (1 mL) was
added 0.25 M NaOH (0.13 mL). The reaction mixture was stirred at room temperature for 2
h and then the solvent was eliminated under high vacuum. The 4-thio-UMP sodium salt
obtained was suspended in dry DMF (2 mL) and 1-iodohexane (0.19 mL, 1.28 mmol) was
added. The reaction mixture was stirred at 90 °C for 4 h, the progress of the reaction was
monitored by analytical HPLC (System A). The solvent was removed in vacuo to obtain
compound 50 as a crude solid, which then was used directly in the next step without further
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purification. For characterization purposes a small portion of compound 50 was purified by
ion-exchange column chromatography as described in procedure A. 1H NMR (D2O) δ 8.21
(d, J=7.5 Hz, 1H), 6.73 (d, J=7.5 Hz, 1H), 5.97 (m, 1H), 4.34 (m, 3H), 4.29 (m, 1H), 4.14
(m, 1H), 3.18 (t, J=7.1 Hz, 2H), 1.74 (m, 2H), 1.46 (m, 2H), 1.33 (m, 4H), 0.89 (t, J=6.9 Hz,
3H); 31P NMR (D2O) δ 0.60; HRMS m/z found 423.0995 (M – H+)-. C15H24N2O8PS
requires 423.0991; HPLC (System A) 15.1 min (99%), (System C) 13.7 min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-4-
(hexylthio)pyrimidin-2(1H)-one, Ammonium salt (30)
To a solution of the crude solid containing compound 50 in DMF (1.5 mL) was added 1,1′-
carbonyldiimidazole (26 mg, 0.16 mmol). The reaction mixture was stirred at room
temperature for 6 h. Then 5% triethylamine solution in 1/1 water/methanol (3 mL) was
added and stirring was continued at room temperature for additional 2 h. After removal of
the solvent, the residue was dried in high vacuum and dissolved in DMF (1 mL). To this
solution was successively added tributylamine (0.11 mL, 0.46 mmol) and a solution 0.35 M
of bis(tributylammonium) salt of phosphoric acid in DMF (0.4 mL). The reaction mixture
was stirred at room temperature for 2 days and then 0.2 M triethylammonium bicarbonate
was added. After removal of the solvent, the residue was purified using the same method
than in procedure A to afford 30 (3.4 mg, 21% from 47) as a white solid. 1H NMR (D2O) δ
8.21 (d, J=7.4 Hz, 1H), 6.75 (d, J=7.4 Hz, 1H), 5.96 (d, J=2.7 Hz, 1H), 4.36 (m, 4H), 4.25
(m, 1H), 3.17 (t, J=7.2 Hz, 2H), 1.73 (m, 2H), 1.45 (m, 2H), 1.32 (m, 4H), 0.88 (t, J=7.1 Hz,
3H); 31P NMR (D2O) δ -9.67, -10.83; HRMS m/z found 503.0606 (M – H+)-.
C15H25N2O11P2S requires 503.0654; HPLC (System A) 18.9 min (99%), (System C) 13.8
min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(diphosphoryloxymethyl)tetrahydrofuran-2-yl)-5-
iodopyrimidine-2,4(1H,3H)-dione, Ammonium salt (32)
To a solution of 53 (8 mg, 0.02 mmol) in DMF (2 mL) was added 1,1′-carbonyldiimidazole
(16 mg, 0.10 mmol). The reaction mixture was stirred at room temperature for 6 h. Then 5%
triethylamine solution in 1/1 water/methanol (2 mL) was added and stirring was continued at
room temperature for additional 2 h. After removal of the solvent, the residue was dried in
high vacuum and dissolved in DMF (2 mL). To this solution was successively added
tributylamine (0.07 mL, 0.29 mmol) and a solution 0.35 M of bis(tributylammonium) salt of
phosphoric acid in DMF (0.3 mL). The reaction mixture was stirred at room temperature for
3 days and then 0.2 M triethylammonium bicarbonate (2 mL) was added, and stirred for 30
min. After removal of the solvent, the residue was purified using the same method than in
procedure A to afford 32 (1.8 mg, 19%) as a white solid. 1H NMR (D2O) δ 8.28 (s, 1H),
5.93 (d, J=4.2 Hz, 1H), 4.42 (m, 2H), 4.25 (m, 3H); 31P NMR (D2O) δ -6.89, -10.60; HRMS
m/z found 528.8901 (M – H+)-. C9H12N2O12P2I requires 528.8910; HPLC (System A) 14.7
min (99%), (System B) 8.8 min (99%).
(2R,3S,4R,5R)-1-(3-Fluoro-4-hydroxy-5-(monophosphoryloxymethyl)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione, Ammonium salt (54)
A solution of 2′-fluoro-2′-deoxy-β-D-arabinofuranosyluridine (15 mg, 0.06 mmol) and
proton sponge (26 mg, 0.12 mmol) in trimethyl phosphate (2 mL) was stirred for 10 min at 0
°C. Then phosphorous oxychloride was added dropwise (0.01mL, 0.12 mmol), and the
reaction mixture was stirred for 2 hours at 0 °C. Then 0.2 M triethylammonium bicarbonate
solution (7 mL) was added, and the clear solution was stirred at room temperature for 45
min. The latter was lyophilized overnight. The residue was purified using the same method
than in procedure A to afford 54 (7 mg, 60%) as a white solid. 1H NMR (D2O) δ 7.90 (d,
J=8.1 Hz, 1H), 6.31 (dd, J=15.9, 4.2 Hz, 1H), 5.89 (d, J=8.1 Hz, 1H), 5.21 (apparent dt,
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JH-F=51.6 Hz, 1H), 4.52 (apparent dt, JH-F=19.2 Hz, 1H), 4.13 (m, 3H); 31P NMR (D2O) δ
4.01; HRMS m/z found 325.0240 (M – H+)-. C9H11N2O8FP requires 325.0237; HPLC
(System A) 10.1 min (99%), (System B) 6.2 min (99%).
(2R,3S,4R,5R)-1-(3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl)pyrimidine-2,4(1H,3H)-dione cyclic-4,5-diphosphate, Ammonium Salt (33)
To a solution of 54 (5 mg, 0.02 mmol) in DMF (2 mL) was added 1,1′-carbonyldiimidazole
(12 mg, 0.08 mmol). The reaction mixture was stirred at room temperature for 8 h. Then 5%
triethylamine in methanol was added and stirring was continued at room temperature for
additional 2 h. After removal of the solvent, the residue was dried in high vacuum and
dissolved in DMF (1 mL). To this solution was successively added tributylamine (0.06 mL,
0.25 mmol) and a solution 0.35 M of bis(tributylammonium) salt of phosphoric acid in DMF
(0.23 mL). The reaction mixture was stirred at room temperature for 3 days and then 0.2 M
triethylammonium bicarbonate (2 mL) was added, and stirred for 30 min. After removal of
the solvent, under reduced pressure at 50 °C, the residue was purified using the same method
than in procedure A to afford 33 (1.6 mg, 29%) as a white solid. 1H NMR (D2O) δ 7.78 (d,
J=8.1 Hz, 1H), 6.35 (dd, J=13.1, 5.3 Hz, 1H), 5.92 (d, J=8.1 Hz, 1H), 5.50 (apparent dt,
JH-F=52.2 Hz, 1H), 4.47 (m, 1H), 4.25 (m, 3H); 31P NMR (D2O) δ -7.15, -10.37; HRMS m/
z found 386.9783 (M – H+)-. C9H10N2O10P2F requires 386.9795; HPLC (System A) 13.2
min (99%), (System B) 8.6 min (99%).
(2R,3R,4S,5R)-1-(3,4-Dihydroxy-5-(monophosphoryloxymethyl)tetrahydrofuran-2-yl)-4-
(ethylthio)pyrimidin-2(1H)-one, Ammonium salt (51)
To a solution of 4-thiouridine 5′-monosphate (10 mg, 0.03 mmol) in MeOH (1 mL) was
added 0.25 M NaOH (0.13 mL). The reaction mixture was stirred at room temperature for 2
h and then the solvent was eliminated under high vacuum. The 4-thio-UMP sodium salt
obtained was suspended in dry DMF (2 mL) and iodoethane (0.1 mL, 1.28 mmol) was
added. The reaction mixture was stirred at 70 °C for 2 h, the progress of the reaction was
monitored by analytical HPLC (System A). The solvent was removed in vacuo to obtain
compound 51 as a crude solid, which then was used directly in the next step without further
purification. For characterization purposes a small portion of compound 51 was purified by
ion-exchange column chromatography as described in procedure A. 1H NMR (D2O) δ 8.26
(d, J=7.4 Hz, 1H), 6.73 (d, J=7.4 Hz, 1H), 5.96 (m, 1H), 4.33 (m, 3H), 4.24 (m, 1H), 4.09
(m, 1H), 3.15 (q, J=7.4 Hz, 2H), 1.36 (t, J=7.4 Hz, 3H); 31P NMR (D2O) δ 1.48; HRMS m/z
found 367.0377 (M – H+)-. C11H16N2O8PS requires 367.0365; HPLC (System A) 8.5 min
(98%), (System B) 6.7 min (98%).
P1,P2-Bis-5-[(2R,3R,4S,5R)-1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-
(ethylthio)pyrimidin-2(1H)-one]pyrophosphate, Ammonium salt, (4-SEt)Up2(4-SEt)U (35)
To a solution of the crude solid containing compound 51 in DMF (1.5 mL) was added 1,1′-
carbonyldiimidazole (26 mg, 0.16 mmol). The reaction mixture was stirred at room
temperature for 6 h. Then 5% triethylamine solution in 1/1 water/methanol (3 mL) was
added and stirring was continued at room temperature for additional 2 h. After removal of
the solvent, the residue was dried in high vacuum and dissolved in DMF (1 mL). To this
solution was successively added tributylamine (0.11 mL, 0.46 mmol) and a solution 0.35 M
of bis(tributylammonium) salt of phosphoric acid in DMF (0.4 mL). The reaction mixture
was stirred at room temperature for 2 days and then 0.2 M triethylammonium bicarbonate
was added. After removal of the solvent, the residue was purified using the same method
than in procedure A to afford 35 (5 mg, 52% from 47) as a white solid. 1H NMR (D2O) δ
8.10 (d, J=7.4 Hz, 2H), 6.57 (d, J=7.4 Hz, 2H), 5.95 (d, J=2.7 Hz, 2H), 4.45 (m, 2H), 4.28
(m, 8H), 3.10 (q, J=7.5 Hz, 4H), 1.35 (t, J=7.5 Hz, 6H); 31P NMR (D2O) δ -10.23; HRMS
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m/z found 717.0711 (M – H+)-. C22H31N4O15P2S2 requires 717.0703; HPLC (System A)




Procedure C Compound 36 (5 mg, 45% from 47) was obtained as a white solid using
benzyl bromide and stirring overnight at room temperature in the alkylation reaction. 1H
NMR (D2O) δ 8.11 (d, J=7.2 Hz, 2H), 7.47 (m, 4H), 7.37 (m, 6H), 6.55 (d, J=7.2 Hz, 2H),
5.92 (d, J=2.4 Hz, 2H), 4.31 (m, 14H); 31P NMR (D2O) δ -10.81; HRMS m/z found
841.0991 (M – H+)-. C32H35N4O15P2S2 requires 841.1016; HPLC (System A) 19.2 min
(99%), (System C) 16.8 min (99%).
Assay of P2Y6 receptor-stimulated PLC activity
A stable cell line expressing the human P2Y6 receptor in 1321N1 human astrocytoma cells
was generated as previously described in detail.16 Agonist-induced [3H]inositol phosphate
production was measured in 1321N1 cells grown to confluence on 48-well plates. Twelve h
before the assay, the inositol lipid pool of the cells was radiolabeled by incubation in 200 μL
of serum-free inositol-free Dulbecco’s modified Eagle’s medium, containing 0.4 μCi of
myo-[3H]inositol. No changes of medium were made subsequent to the addition of
[3H]inositol. On the day of the assay, cells were challenged with 50 μL of the five-fold
concentrated solution of receptor agonists in 200 mM Hepes (N-(2-hydroxyethyl)-
piperazine-N′-2-ethanesulfonic acid), pH 7.3, containing 50 mM LiCl for 20 min at 37 °C.
Incubations were terminated by aspiration of the drug-containing medium and addition of
450 μL of ice-cold 50 mM formic acid. After 15 min at 4 °C, samples were neutralized with
150 μL of 150 mM NH4OH. [3H]Inositol phosphates were isolated by ion exchange
chromatography on Dowex AG 1-X8 columns as previously described.31
Data Analysis
Agonist potencies (EC50 values) were obtained from concentration-response curves by non-
linear regression analysis using the GraphPad software package Prism (GraphPad, San
Diego, CA). All experiments were performed in triplicate assays and repeated at least three
times. The results are presented as mean ± SEM from multiple experiments or in the case of
concentration effect curves from a single experiment carried out with triplicate assays that
were representative of results from multiple experiments.
Molecular Modeling
Molecular mechanics calculations have been carried out by means of the Discover3 module
of InsightII,40 using the CFF91 forcefield.41 The receptor model used for the docking
experiments was the P2Y6/UDP complex which we previously built11 and optimized by
means of a molecular dynamics (MD) simulation in an explicit fully hydrated lipid bilayer.35
Before performing the docking experiments, the ligands were first fully optimized by means
of quenched molecular dynamics followed by energy minimization. An NVT (constant-
volume/constant-temperature) molecular dynamic simulation was carried out at constant
temperature of 300 K for 10 ps, using a time step of 1 fs. During the simulation, snapshots of
the system were taken at regular intervals of 1 ps. The structures in each snapshot were
energy minimized (BFGS Newton method) until an RMSD (root mean squared) of 0.00001
kcal/mol/Å on the gradient was reached. For each ligand, the conformation showing the
lowest energy was promoted to the next phase of the study.
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Subsequently, the ligands were flexibly superimposed to the bound conformation of 1, as
derived from our MD simulation.35 The flexible superimpositions have been carried out by
means of the FieldFit program of the Search Compare module of InsightII,40 giving equal
weight to the steric and the electrostatic factors. The bound conformation of 1 was kept rigid
during the calculation, while the structures to be superimposed were fully flexible. An
alignment of the molecules based on their dipole and quadruple moments was used as the
starting position.
The docking experiments were carried out by means of the Monte Carlo minimization
approach implemented in the Affinity module of InsightII.40 The binding site was defined as
all the residues within a distance of 6 Å from the ligand. Full flexibility was granted to the
ligands and to the residues of the binding site. The scaling factor for the van der Waals term
was set at 0.1, while the coulombic term was set at 1. The maximum movement in each
random translation and rotation of the ligand were set at 0.1 Å and 1° respectively.
After the docking procedure, the receptor-ligand complexes were optimized by means of a
Monte Carlo Multiple Minimum (MCMM)42 conformational search as implemented in
MacroModel.43,44 The search was performed on the ligand and the residues located within a
distance of 6 Å from the ligand, while the remaining residues were conformationally frozen.
The following parameters were employed for the conformational search: number of steps =
100; number of structures to save for each search = 100; energy window for saving
structures = 1000.0 KJ/mol. The calculations were conducted with the MMFFs force field,45
using water as implicit solvent (GB/SA model as implemented in MacroModel)46 and a
molecular dielectric constant of 1. For the energy minimizations the Polak-Ribier Conjugate
Gradient was used with a convergence threshold on the gradient of 0.05 kJ/Å/mol.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Molecular models of the complexes of the human P2Y6 receptor with UDP analogues 32, (a
and b, 5-iodo), 6 (c, (S)-methanocarba), 31 (d, 3-methyl), 23 (e, 4-ethylthio), and 28 (f, 4-
carboxyethylthio). In all cases, the diphosphate moiety of the nucleotide is coordinated by
three cationic residues from TM3 (3.29), TM6 (6.55), and TM7 (7.39). The donation of an
H-bond from the NH at position 3 of the uracil ring to Y33(1.39) seems to contribute to
higher potency in the activation of the P2Y6 receptor. To facilitate the comparison, in the six
panels of this figure the receptor maintains the same orientation relative to the plane of the
membrane.
In the schematic representation of the P2Y6 receptor complexed with Cpd. 32 (a), the tube
represents the backbone of the receptor and is colored according to residue positions, with a
spectrum of colors that ranges from red (N-terminus) to purple (Cterminus): TM1 is in
orange, TM2 in ochre, TM3 in yellow, TM4 in green, TM5 in cyan, TM6 in blue, TM7 in
purple.
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Graphical representation of the pseudorotational cycle,48 which defines all of the possible
ribose ring conformations. The phase angle of pseudorotation (P) describes the geometry of
the ribose puckering. The (N)-methanocarba ring system adopts a C2′-exo conformation and
the (S)-methanocarba ring system a C3′-exo conformation. The 2-OBH ring system
maintains a C1′-exo conformation, in the (S) region.
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Preparation of ribose- and uracil-modified UDP analogues. Reagents and conditions: (i) (1)
POCl3, proton sponge, PO(OMe)3, 0 °C; (2) (Bu3NH+)2PO4H, Bu3N, DMF, 0 °C; (ii)
CF3COOEt, DIEA, DMF, rt. (iii) H2, Pd/C, MeOH, rt.
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Preparation of 2-OBH UDP analogue. Reagents and conditions: (i) (1) POCl3, proton
sponge, PO(OMe)3, 0 °C; (2) (Bu3NH+)2PO4H, Bu3N, DMF, 0 °C.
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Preparation of 4-substituted-thio-UDP analogues. Procedure B. Reagents and conditions: (i)
(1) 0.25 M NaOH, MeOH, rt; (2) RX, DMF, rt; (ii) 0.25 M NaOH, H2O, rt.
Besada et al. Page 23














Preparation of 4-substituted-thio-UDP analogues. Procedure C. Reagents and conditions: (i)
(1) 0.25 M NaOH, MeOH, rt; (2) R1X, DMF, 90 °C; (ii) (1) 1,1’-carbonyldiimidazole,
DMF, rt; (2) Et3N 5% in H2O/MeOH 1/1, rt; (3) (Bu3NH+)2PO4H, Bu3N, DMF, rt; (iii) 0.25
M NaOH, H2O, rt.
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Preparation of 5-halo and phosphate- and ribose-modified UDP analogues. Reagents and
conditions: (i) POCl3, proton sponge, PO(OMe)3, 0 °C; (ii) (1) 1,1’- carbonyldiimidazole,
DMF, rt; (2) Et3N 5% in MeOH, rt; (3) (Bu3NH+)2PO4H2-, Bu3N, DMF, rt.
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Structures of UDP and various analogues and the reported EC50 values in stimulation of
PLC through the recombinant P2Y6 receptor (human, unless noted).16,22,23,24,35 The EC50
for INS48823 is similar to UDP.18
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Table 1
In vitro pharmacological data for UDP, 1, and its analogues in the stimulation of PLC at recombinant human
P2Y6 receptors expressed in 1321N1 astrocytoma cells. Unless noted: R1, R3, R5, R6 = H; R2, R4 = O; and R7,
R8 = OH.
Compound Modification Structure EC50 at hP2Y6 receptor, μMa
1 (= UDP) 0.013 ± 0.004
11 (= UMP) NE
Ribose-modified
12 2′-deoxy R7 = H 1.72 ± 0.76
13 3′-deoxy R8 = H 2.5 ± 0.8
14 (= 2′-deoxyuridine-bisphosphate) c NE
15 2 ′-deoxy-2′-azido R7 = N3 1.5 ± 0.4
16 2′-deoxy-2′-amino R7 = NH2 3.9 ± 0.9
17 2′-deoxy-2′-amino 3′-diphosphate c NE
18 2′-fluoro-2′-deoxyara R7 = H, R6 = F 5.5 ± 0.5
5 (N)-methanocarba d NE
6 (S)-methanocarba-2′-deoxy d 0.23 ± 0.05
19 3′,4′-cyclopropylb c 3.5 ± 0.8
Uracil-modified
20 2-thio R2 = S 0.06 ± 0.01
21 4-thio R4 = S 0.08 ± 0.04
22 4-methylthio R4 = SCH3 2.3 ± 0.6
23 4-ethylthio R4 = SCH2CH3 0.28 ± 0.02
24 4-allylthio R4 = SCH2-CH=CH2 0.56 ± 0.09
25 4-benzylthio R4 = SCH2C6H5 0.80 ± 0.05
26 4-carboxymethylthio R4 = SCH2CO2H 1.7 ± 0.3
27 4-carboxamido-methylthio R4 = SCH2CONH2 18 ± 9
28 4-carboxyethylthio R4 = S(CH2)2COOH 1.1 ± 0.2
29 4-carboxypropylthio R4 = S(CH2)3COOH 8.8 ± 2.0
30 4-hexylthio R4 = S(CH2)5CH3 4.9 ± 0.2
31 3-methyl R3 = CH3 3.3 ± 1.0
32 5-iodo R5 = I 0.015 ± 0.002
Phosphate-and ribose modified
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Compound Modification Structure EC50 at hP2Y6 receptor, μMa
33 Cyclic 3′,5′-diphosphate and 2′-ara-F c NE
Dinucleotides
34 Up2U R1 = uridine-5′- 2.3 ± 0.9
35 U(4-ethylthio) p2U(4-ethylthio) R1 = 4-SCH2CH3-uridine-5′-, R4 = SCH2CH3 <50% at 10 μM
36 U(4-benzylthio) p2U(4-benzylthio) R1 = 4-SCH2C6H5-uridine-5′-, R4 = SCH2C6H5 <50% at 10 μM
37 Cp2C R1 = cytidine-5′-, R4 = NH NE
a
Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA).
EC50 values (mean ± standard error) represent the concentration at which 50% of the maximal effect is achieved. Relative efficacies (%) were
determined by comparison with the effect produced by a maximal effective concentration of reference agonist (UDP) in the same experiment. If no
maximal effect is given, then 100% efficacy was achieved.
b
oxabicyclohexane ring system (2-OBH)25.
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